Diagnosis and management of diabetes: Synopsis of the 2016 American diabetes association standards of medical care in diabetes

Annals of Internal Medicine

Volumn 164, Issue 8, 2016, Pages 542-552

  Chamberlain, James J ^a   Rhinehart, Andrew S ^b   Shaefer, Charles F ^c   Neuman, Annie ^a  

^a St Mark's Hospital Salt Lake City   (United States)

^b Glytec   (United States)

^c University Primary Care Physicians   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; METABOLISM; PRACTICE GUIDELINE; PREDIABETIC STATE; RISK FACTOR;

ADULT; BLOOD GLUCOSE SELF-MONITORING; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PREDIABETIC STATE; RISK FACTORS;

EID: 84964495115     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-3016     Document Type: Article

References (70)

1. American Diabetes Association. Classification and diagnosis of diabetes. In: 2016 Standards of Medical Care in Diabetes. Diabetes Care. 2016; 39:S13-22. Accessed at http://care.diabetesjournals.org/content/39/Supplement-1/S13.full.pdf on 8 February 2016.
2. International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327-34. [PMID: 19502545] doi:10.2337/dc09-9033
3. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33:676-82. [PMID: 20190296] doi:10.2337/dc09-1848
4. Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements. 2013; 29:1-31. [PMID: 23748438]
5. Erickson SC, Le L, Zakharyan A, Stockl KM, Harada AS, Borson S, et al. New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc. 2012; 60:474-9. [PMID: 22288652] doi:10.1111/j.1532-5415.2011 .03842.x
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. [PMID: 8366922]
7. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010; 33:1090-6. [PMID: 20150297] doi:10.2337/dc09-1941
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12. [PMID: 10938048]
9. Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care. 2014; 37:1048-51 [PMID: 24513588] doi:10.2337/dc13-2173
10. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008; 31:1473-8. [PMID: 18540046] doi:10.2337/dc08-0545
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65. [PMID: 9742977]
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. [PMID: 9742976]
13. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33:1578-84. [PMID: 20215456] doi: 10.2337/dc10-0125
14. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39. [PMID: 19092145] doi:10.1056/NEJMoa0808431
15. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-72. [PMID: 18539916] doi:10.1056/NEJMoa 0802987
16. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015; 175:356-62. [PMID: 25581565] doi:10.1001/jamainternmed.2014.7345
17. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med. 2014; 174:1227-34 [PMID: 24979148] doi:10.1001/jamainternmed.2014.2894
18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140-9. [PMID: 25538310] doi:10.2337/dc14-2441
19. Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012; 157:336-47. [PMID: 22777524]
20. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643-53. [PMID: 16371630]
21. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289:2254-64. [PMID: 12734137]
22. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28:950-5. [PMID: 15793205]
23. Chamberlain JJ, Dopita D, Gilgen E, Neuman A. Impact of frequent and persistent use of continuous glucose monitoring (CGM) on hypoglycemia fear, frequency of emergency medical treatment, and SMBG frequency after one year. J Diabetes Sci Technol. 2015. [PMID: 26353781]
24. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369:224-32. [PMID: 23789889] doi:10.1056/NEJ Moa1303576
25. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89. [PMID: 18784090] doi:10.1056/NEJ Moa0806470
26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65. [PMID: 9742977]
27. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312:2668-75. [PMID: 25536258] doi:10.1001/jama.2014.15298
28. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373:232-42. [PMID: 26052984] doi:10.1056/NEJMoa1501352
29. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014; 384:2228-34. [PMID: 25220191] doi:10.1016/S0140-6736(14)61335-0
30. MannKind Corporation. Briefing document: endocrinologic and metabolic drug advisory committee: AFREZZA (insulin human [rDNA origin]) inhalation powder: an ultra-rapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus. 1 April 2014. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM390865.pdf on 11 December 2015.
31. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 15 May 2015. Accessed at www.fda.gov/Drugs/DrugSafety/ucm475463.htm on 11 December 2015.
32. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al; American Heart Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007; 30:162-72. [PMID: 17192355]
33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358:580-91. [PMID: 18256393] doi:10.1056/NEJMoa 0706245
34. Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Health Care Statistics. Crude and ageadjusted hospital discharge rates for major cardiovascular disease as first-listed diagnosis per 1, 000 diabetic population, United States, 1988-2006. Atlanta, GA: Centers for Disease Control and Prevention; 2014. Accessed at www.cdc.gov/diabetes/statistics/cvdhosp/cvd/fig3.htm on 30 November 2015.
35. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013; 10:CD008277. [PMID: 24170669] doi:10.1002/14651858.CD008277.pub2
36. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and metaanalysis. Arch Intern Med. 2012; 172:1296-303. [PMID: 22868819] doi:10.1001/archinternmed.2012.3147
37. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. [PMID: 9571349]
38. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52. [PMID: 9486993]
39. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355:253-9. [PMID: 10675071]
40. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547-59. [PMID: 18378520] doi:10.1056/NEJMoa0801317
41. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-97. [PMID: 26039521] doi:10.1056/NEJMoa1410489
42. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37:2864-83. [PMID: 25249672] doi:10.2337/dc14-1296
43. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995; 47:1703-20. [PMID: 7643540]
44. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37:2864-83. [PMID: 25249672] doi:10.2337/dc14-1296
45. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997; 314:783-8. [PMID: 9080995]
46. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995; 47:1703-20. [PMID: 7643540]
47. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. [PMID: 9732337]
48. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355:253-9. [PMID: 10675071]
49. Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, et al. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol. 2012; 47:S1-30, S31-54. [PMID: 22632804] doi:10.1016/j.jcjo.2011.12.025
50. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014; 14:528. [PMID: 25139473] doi:10.1007/s11892-014-0528-7
51. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37:31-8. [PMID: 24356595] doi:10.2337/dc13-2114
52. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376:419-30. [PMID: 20594588] doi:10.1016/S0140-6736(10)60576-4
53. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009; 301: 1547-55. [PMID: 19366774] doi:10.1001/jama.2009.476
54. Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013; 6:79-92. [PMID: 23403729] doi:10.2147/DMSO.S37415
55. Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Curr Diab Rep. 2009; 9: 423-31. [PMID: 19954686]
56. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al; American Diabetes Association. Comprehensive foot examination and risk assessment: a report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008; 31:1679-85. [PMID: 18663232] doi: 10.2337/dc08-9021
57. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54:e132-73. [PMID: 22619242] doi:10.1093/cid/cis346
58. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003; 26:3333-41. [PMID: 14633825]
59. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27:553-91. [PMID: 14747243]
60. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32:1119-31. [PMID: 19429873] doi:10.2337/dc09-9029
61. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345:1359-67. [PMID: 11794168]
62. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360:1283-97. [PMID: 19318384] doi:10.1056/NEJMoa0810625
63. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569-619. [PMID: 22922416] doi:10.1093/eurheartj/ehs215
64. Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013; 36:2169-74. [PMID: 23435159] doi:10.2337/dc12-1988
65. Maynard G, Wesorick DH, O'Malley C, Inzucchi SE; Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med. 2008; 3:29-41. [PMID: 18951386] doi:10.1002/jhm.354
66. Curll M, Dinardo M, Noschese M, Korytkowski MT. Menu selection, glycaemic control and satisfaction with standard and patientcontrolled consistent carbohydrate meal plans in hospitalised patients with diabetes. Qual Saf Health Care. 2010; 19:355-9. [PMID: 20693224] doi:10.1136/qshc.2008.027441
67. Draznin B, Gilden J, Golden SH, Inzucchi SE, Baldwin D, Bode BW, et al; PRIDE investigators. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care. 2013; 36:1807-14. [PMID: 23801791] doi:10.2337/dc12-2508
68. Schmeltz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, O'Shea-Mahler E, Johnson D, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care. 2007; 30:823-8. [PMID: 17229943]
69. Shomali ME, Herr DL, Hill PC, Pehlivanova M, Sharretts JM, Magee MF. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study. Diabetes Technol Ther. 2011; 13:121-6. [PMID: 21284478] doi:10.1089/dia .2010.0124
70. Shepperd S, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev. 2013; 1:CD000313. [PMID: 23440778] doi:10.1002/14651858.CD000313.pub4